S&P 500   3,921.35 (-0.69%)
DOW   31,871.54 (-0.73%)
QQQ   308.15 (-0.52%)
AAPL   158.74 (-0.12%)
MSFT   278.47 (+0.29%)
META   205.25 (+0.47%)
GOOGL   104.68 (-0.87%)
AMZN   96.92 (-1.81%)
TSLA   189.28 (-1.53%)
NVDA   265.79 (-2.25%)
NIO   9.02 (-2.70%)
BABA   86.55 (+0.03%)
AMD   97.64 (-2.63%)
T   18.40 (-0.33%)
F   11.34 (-0.70%)
MU   61.12 (-0.36%)
CGC   1.91 (+0.00%)
GE   91.32 (-0.29%)
DIS   93.25 (-2.69%)
AMC   4.42 (-1.12%)
PFE   40.00 (-0.45%)
PYPL   72.66 (+0.14%)
NFLX   328.99 (+2.69%)
S&P 500   3,921.35 (-0.69%)
DOW   31,871.54 (-0.73%)
QQQ   308.15 (-0.52%)
AAPL   158.74 (-0.12%)
MSFT   278.47 (+0.29%)
META   205.25 (+0.47%)
GOOGL   104.68 (-0.87%)
AMZN   96.92 (-1.81%)
TSLA   189.28 (-1.53%)
NVDA   265.79 (-2.25%)
NIO   9.02 (-2.70%)
BABA   86.55 (+0.03%)
AMD   97.64 (-2.63%)
T   18.40 (-0.33%)
F   11.34 (-0.70%)
MU   61.12 (-0.36%)
CGC   1.91 (+0.00%)
GE   91.32 (-0.29%)
DIS   93.25 (-2.69%)
AMC   4.42 (-1.12%)
PFE   40.00 (-0.45%)
PYPL   72.66 (+0.14%)
NFLX   328.99 (+2.69%)
S&P 500   3,921.35 (-0.69%)
DOW   31,871.54 (-0.73%)
QQQ   308.15 (-0.52%)
AAPL   158.74 (-0.12%)
MSFT   278.47 (+0.29%)
META   205.25 (+0.47%)
GOOGL   104.68 (-0.87%)
AMZN   96.92 (-1.81%)
TSLA   189.28 (-1.53%)
NVDA   265.79 (-2.25%)
NIO   9.02 (-2.70%)
BABA   86.55 (+0.03%)
AMD   97.64 (-2.63%)
T   18.40 (-0.33%)
F   11.34 (-0.70%)
MU   61.12 (-0.36%)
CGC   1.91 (+0.00%)
GE   91.32 (-0.29%)
DIS   93.25 (-2.69%)
AMC   4.42 (-1.12%)
PFE   40.00 (-0.45%)
PYPL   72.66 (+0.14%)
NFLX   328.99 (+2.69%)
S&P 500   3,921.35 (-0.69%)
DOW   31,871.54 (-0.73%)
QQQ   308.15 (-0.52%)
AAPL   158.74 (-0.12%)
MSFT   278.47 (+0.29%)
META   205.25 (+0.47%)
GOOGL   104.68 (-0.87%)
AMZN   96.92 (-1.81%)
TSLA   189.28 (-1.53%)
NVDA   265.79 (-2.25%)
NIO   9.02 (-2.70%)
BABA   86.55 (+0.03%)
AMD   97.64 (-2.63%)
T   18.40 (-0.33%)
F   11.34 (-0.70%)
MU   61.12 (-0.36%)
CGC   1.91 (+0.00%)
GE   91.32 (-0.29%)
DIS   93.25 (-2.69%)
AMC   4.42 (-1.12%)
PFE   40.00 (-0.45%)
PYPL   72.66 (+0.14%)
NFLX   328.99 (+2.69%)
NASDAQ:ARQT

Arcutis Biotherapeutics - ARQT Stock Forecast, Price & News

$10.31
-0.49 (-4.54%)
(As of 03/24/2023 10:56 AM ET)
Add
Compare
Today's Range
$10.29
▼
$10.92
50-Day Range
$10.80
▼
$17.14
52-Week Range
$10.29
▼
$27.40
Volume
110,339 shs
Average Volume
918,048 shs
Market Capitalization
$629.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00

Arcutis Biotherapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
350.2% Upside
$47.00 Price Target
Short Interest
Bearish
28.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.03mentions of Arcutis Biotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$537,319 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.68) to ($2.76) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

721st out of 989 stocks

Pharmaceutical Preparations Industry

350th out of 480 stocks

See Top Rated MarketRank™ Stocks Here

ARQT stock logo

About Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARQT Stock News Headlines

March 19, 2023 | americanbankingnews.com
Needham & Company LLC Cuts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $24.00
March 16, 2023 | americanbankingnews.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Sees Large Volume Increase
March 24, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
March 14, 2023 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Illumina (ILMN) and Arcutis Biotherapeutics (ARQT)
March 9, 2023 | finance.yahoo.com
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
March 2, 2023 | finance.yahoo.com
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2022 Earnings Call Transcript
March 2, 2023 | finance.yahoo.com
Investors in Arcutis Biotherapeutics (NASDAQ:ARQT) from three years ago are still down 40%, even after 5.0% gain this past week
March 1, 2023 | finance.yahoo.com
Q4 2022 Arcutis Biotherapeutics Inc Earnings Call
March 24, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
March 1, 2023 | markets.businessinsider.com
Morgan Stanley Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
March 1, 2023 | finance.yahoo.com
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023 | msn.com
Arcutis Biotherapeutics's Earnings Outlook
February 21, 2023 | finance.yahoo.com
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
February 9, 2023 | seekingalpha.com
Arcutis Biotherapeutics: Market Discounting Zoryve Momentum
February 8, 2023 | finance.yahoo.com
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
January 17, 2023 | finance.yahoo.com
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
January 14, 2023 | finance.yahoo.com
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
January 5, 2023 | forbes.com
Arcutis Biotherapeutics
December 23, 2022 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Arcutis Biotherapeutics (ARQT)
December 19, 2022 | finance.yahoo.com
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
December 12, 2022 | seekingalpha.com
Arcutis says second Phase 3 trial for atopic dermatitis therapy reached main goal
December 12, 2022 | marketwatch.com
Arcutis: Roflumilast Hits Goals Again in Atopic Dermatitis Study >ARQT
December 12, 2022 | finance.yahoo.com
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
December 5, 2022 | finance.yahoo.com
Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
December 1, 2022 | markets.businessinsider.com
Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
December 1, 2022 | finance.yahoo.com
MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis
November 28, 2022 | finance.yahoo.com
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
See More Headlines
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARQT Company Calendar

Last Earnings
11/04/2021
Today
3/24/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARQT
CUSIP
N/A
CIK
1787306
Web
www.arcutis.com
Phone
805-418-5006
Fax
N/A
Employees
147
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$47.00
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+335.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-311,460,000.00
Net Margins
N/A
Pretax Margin
-8,449.76%
Return on Equity
-134.03%
Return on Assets
-76.77%

Debt

Debt-to-Equity Ratio
0.94
Current Ratio
11.57
Quick Ratio
11.37

Sales & Book Value

Annual Sales
$3.69 million
Price / Sales
178.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.44 per share
Price / Book
3.14

Miscellaneous

Outstanding Shares
61,080,000
Free Float
47,034,000
Market Cap
$659.66 million
Optionable
Not Optionable
Beta
0.52

Social Links


Key Executives

  • Mr. Todd Franklin Watanabe M.A.Mr. Todd Franklin Watanabe M.A. (Age 55)
    Pres, CEO & Director
    Comp: $940.2k
  • Dr. Bhaskar Chaudhuri Ph.D. (Age 68)
    Co-Founder & Independent Director
    Comp: $60.58k
  • Mr. Scott L. BurrowsMr. Scott L. Burrows (Age 46)
    CFO & Principal Accounting Officer
    Comp: $617.87k
  • Dr. David W. Osborne Ph.D. (Age 62)
    Chief Technical Officer
    Comp: $584.55k
  • Dr. Patrick E. Burnett M.D. (Age 51)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $700.1k
  • Mr. Matthew Richard Moore (Age 49)
    Sr. VP & Chief Bus. Officer
    Comp: $560.07k
  • Ms. Patricia A. TurneyMs. Patricia A. Turney (Age 56)
    Sr. VP of Operations
  • Mr. Eric McIntyre
    Head of Investor Relations
  • Ms. Courtney Barton (Age 40)
    VP and Chief Compliance Officer & Privacy Officer
  • Mr. Masaru Matsuda Esq. (Age 52)
    J.D., Sr. VP, Gen. Counsel & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ARQT Stock - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARQT shares.
View ARQT analyst ratings or view top-rated stocks.

What is Arcutis Biotherapeutics' stock price forecast for 2023?

6 analysts have issued 1 year price objectives for Arcutis Biotherapeutics' stock. Their ARQT share price forecasts range from $24.00 to $57.00. On average, they predict the company's share price to reach $47.00 in the next year. This suggests a possible upside of 335.2% from the stock's current price.
View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts.

How have ARQT shares performed in 2023?

Arcutis Biotherapeutics' stock was trading at $14.80 at the start of the year. Since then, ARQT stock has decreased by 27.0% and is now trading at $10.80.
View the best growth stocks for 2023 here.

When is Arcutis Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ARQT earnings forecast.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($1.14) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.01.

What ETFs hold Arcutis Biotherapeutics' stock?

ETFs with the largest weight of Arcutis Biotherapeutics (NASDAQ:ARQT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED), ProShares Ultra Nasdaq Biotechnology (BIB) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

(ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

What is Arcutis Biotherapeutics' stock symbol?

Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Avidity Partners Management LP (2.88%), GW&K Investment Management LLC (2.55%), Jennison Associates LLC (2.29%), Barclays PLC (1.94%), Point72 Asset Management L.P. (1.81%) and Allspring Global Investments Holdings LLC (1.75%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcutis Biotherapeutics' stock price today?

One share of ARQT stock can currently be purchased for approximately $10.80.

How much money does Arcutis Biotherapeutics make?

Arcutis Biotherapeutics (NASDAQ:ARQT) has a market capitalization of $659.66 million and generates $3.69 million in revenue each year. The company earns $-311,460,000.00 in net income (profit) each year or ($5.65) on an earnings per share basis.

How many employees does Arcutis Biotherapeutics have?

The company employs 147 workers across the globe.

How can I contact Arcutis Biotherapeutics?

Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The official website for the company is www.arcutis.com. The company can be reached via phone at 805-418-5006 or via email at ir@arcutis.com.

This page (NASDAQ:ARQT) was last updated on 3/24/2023 by MarketBeat.com Staff